Semaglutide and Liraglutide injectables added to ADIoS

In response to MHRA inspection requirements that NHS Trusts should have a system to monitor changes in usage trends of GLP-1 agonists to identify diversion, Rx-info has added Semaglutide and Liraglutide injections as monitored drugs in ADIoS.

Reporting of these items will become visible to ADIoS subscribers from 30/8/24.

These drugs are added to the ADIoS risk list and joins other controlled and diversion risk medicines.